Healthcare institutions and the Ministry of Health of the Republic of Tajikistan organize the monitoring, systematization and analysis of information on the adverse effects of medicinal products and the characteristics of their interaction. This information is periodically submitted to the Ministry of Health of the Republic of Tajikistan.

Currently, the Applicant (Marketing Authorization Holder – MAH) has no obligation to establish and maintain a pharmacovigilance system in the Republic of Tajikistan, and no obligation to provide information on the side effects (adverse events) to medicinal products.

Despite the absence of a mandatory requirement to create and maintain a pharmacovigilance system, Cratia offers services of establishing and maintaining the safety of the medicinal products placed on the market of Tajikistan. We are ready to outsource of a local contact person, to monitor the information on adverse events, literature and websites, periodical review and update the instructions for use.

Cratia provides professional services of the establishment and maintenance of the pharmacovigilance system in Tajikistan. We have an excellent knowledge of national legislation, necessary experience and resources.

To start cooperation or get advice, please contact us by phone: +38 068 064-78-31, +38 044 223-61-67, by e-mail: info@cratia.ua, or visit our office.